Alpha‐synuclein oligomerization and aggregation: A model will always be a model
2021 | journal article; research paper. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Documents & Media
License
Details
- Title Variant(s)
- This is a response to “Monitoring alpha‐synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get”. Read the reply on “Alpha‐Synuclein oligomerization and aggregation: All models are useful but only if we know what they model”. The articles are accompanied by a Preface “How good are cellular models?”.
- Authors
- Outeiro, Tiago Fleming
- Abstract
- Abstract image
The process of a‐syn aggregation is thought to be central in synucleinopathies, but has been difficult to study in the laboratory. Different models attempt to recapitulate specific aspects of the aggregation process. The BiFC assay uses engineered fusion proteins in order to enable the detection of a‐syn dimers and oligomers in living cells. As any model, it has strengths and limitations and, therefore, should only be regarded as a model for the study of basic molecular mechanisms involved in PD and other synucleinopathies. image - Issue Date
- 2021
- Journal
- Journal of Neurochemistry
- Project
- EXC 2067: Multiscale Bioimaging
- Working Group
- RG Outeiro (Experimental Neurodegeneration)
- ISSN
- 0022-3042
- eISSN
- 1471-4159
- Language
- English
- Sponsor
- Deutsche Forschungsgemeinschaft http://dx.doi.org/10.13039/501100001659
